RS51031B - Farmaceutski aktivni estri uridina - Google Patents

Farmaceutski aktivni estri uridina

Info

Publication number
RS51031B
RS51031B YUP-765/03A YUP76503A RS51031B RS 51031 B RS51031 B RS 51031B YU P76503 A YUP76503 A YU P76503A RS 51031 B RS51031 B RS 51031B
Authority
RS
Serbia
Prior art keywords
alkyl chain
carbon atoms
branched
branched alkyl
pharmaceutically active
Prior art date
Application number
YUP-765/03A
Other languages
English (en)
Inventor
Rudy Susilo
Original Assignee
Trommsdorff Gmbh & Co.Kg.Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trommsdorff Gmbh & Co.Kg.Arzneimittel filed Critical Trommsdorff Gmbh & Co.Kg.Arzneimittel
Publication of YU76503A publication Critical patent/YU76503A/sh
Publication of RS51031B publication Critical patent/RS51031B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Jedinjenje, koje ima opštu formulu (I):gdeR predstavlja R"-COO;R' predstavlja vodonik ili hidroksi grupu;R" predstavlja monorazgranati ili multirazgranati alkilni lanac sa 8 do 30 atoma ugljenika, monoenski alkilni lanac sa 8 do 30 atoma ugljenika, monoenski razgranati alkilni lanac sa 8 do 30 atoma ugljenika, polienski alkilni lanac sa 8 do 30 atoma ugljenika, polienski razgranati alkilni lanac sa 8 do 30 atoma ugljenika, razgranati ili nerazgranati alkilni lanac sa 8 do 30 atoma ugljenika, koji sadrži karbociklični ili heterociklični prsten, monoinski alkilni lanac sa 8 do 30 atoma ugljenika, moninski razgranat alkilni lanac sa 8 do 30 atoma ugljenika, poliinski alkilni lanac sa 8 do 30 atoma ugljenika, poliinski razgranat alkilni lanac sa 8 do 30 atoma ugljenika, alkilni lanac sa 8 do 30 atoma ugljenika, koji sadrži najmanje jednu dvogubu ijednu trogubu vezu, razgranati alkilni lanac sa 8 do 30 atoma ugljenika, koji sadrži najmanje jednu dvogubu i jednu trogubu vezu, hidroksi grupa ili tiol grupa, koja sadrži razgranat ili nerazgranat i/ili zasićen ili nezasićen alkilni lanac sa 8 do 30 atoma ugljenika i njihove farmaceutski prihvatljive soli.Prijava sadrži još 24 patentna zahteva.
YUP-765/03A 2001-04-30 2002-04-29 Farmaceutski aktivni estri uridina RS51031B (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01110608 2001-04-30
US28809001P 2001-05-03 2001-05-03
EP01124879 2001-10-18
US33042901P 2001-10-22 2001-10-22

Publications (2)

Publication Number Publication Date
YU76503A YU76503A (sh) 2006-05-25
RS51031B true RS51031B (sr) 2010-10-31

Family

ID=32598659

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP-2010/0077A RS20100077A (en) 2001-04-30 2002-04-29 Pharamceutically active uridine esters
YUP-765/03A RS51031B (sr) 2001-04-30 2002-04-29 Farmaceutski aktivni estri uridina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP-2010/0077A RS20100077A (en) 2001-04-30 2002-04-29 Pharamceutically active uridine esters

Country Status (5)

Country Link
US (4) US7560442B2 (sr)
JP (1) JP4880190B2 (sr)
EA (1) EA200301204A1 (sr)
EE (1) EE201100023A (sr)
RS (2) RS20100077A (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20050158258A1 (en) * 2004-01-21 2005-07-21 Mary Kay Inc. Methods and compositions for the treatment of skin changes associated with aging and environmental damage
US8084500B2 (en) * 2005-01-14 2011-12-27 Nutrition Therapeutics, Inc. Method of using catalpic acid to treat dyslipidemia
US7687544B2 (en) * 2005-01-14 2010-03-30 Nutrition Therapeutics, Inc. Method of using catalpic acid to treat type 2 diabetes and associated disorders
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
WO2007127380A2 (en) * 2006-04-28 2007-11-08 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8329663B2 (en) * 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
WO2009097596A1 (en) * 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
CA2724023C (en) * 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
US8950583B2 (en) 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
WO2010106082A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
JP2013505963A (ja) * 2009-09-28 2013-02-21 ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデイション 汚染された環境から元素を除去するチオール含有化合物およびその使用方法
US8575218B2 (en) * 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US8426368B2 (en) * 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
JP2012041283A (ja) * 2010-08-17 2012-03-01 Porien Project Kk 血管新生抑制剤
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CA2873138A1 (en) * 2012-05-10 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of local pain
CN105916872A (zh) * 2013-10-23 2016-08-31 坎姆根公司 二硫戊环官能化的核苷亚酰胺和用于在固体表面上更牢固固定生物分子的载体
EP3002010A1 (en) * 2014-09-30 2016-04-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling
WO2016008603A1 (en) * 2014-07-16 2016-01-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling
AU2016302005B2 (en) 2015-08-05 2021-03-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2017155386A1 (en) * 2016-03-08 2017-09-14 N.V. Nutricia Method for treating brain atrophy
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US10618927B1 (en) * 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
WO2022251491A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
DE3883374T2 (de) * 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents

Also Published As

Publication number Publication date
EA200301204A1 (ru) 2004-04-29
US7915234B2 (en) 2011-03-29
US20040121979A1 (en) 2004-06-24
US20050043394A1 (en) 2005-02-24
US20050065110A1 (en) 2005-03-24
US7560442B2 (en) 2009-07-14
US20050043269A1 (en) 2005-02-24
RS20100077A (en) 2010-10-31
JP2004531543A (ja) 2004-10-14
EE201100023A (et) 2011-08-15
US7417034B2 (en) 2008-08-26
US7396826B2 (en) 2008-07-08
YU76503A (sh) 2006-05-25
JP4880190B2 (ja) 2012-02-22

Similar Documents

Publication Publication Date Title
RS51031B (sr) Farmaceutski aktivni estri uridina
PT986403E (pt) Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
BR0113961A (pt) Método de analgesia
BR9912029A (pt) Compostos reacionais de amina compreendendo um ou mais ingredientes ativos
TW200633966A (en) 12-aryl prostaglandin analogs
CO4770945A1 (es) Composiciones orales antiplaca que contienen fenol alquila- tado antibacterial
ATE156997T1 (de) Nichtstechende zusammensetzungen mit kühleffekt
DK0651739T3 (da) Hydroxamsyrederivater som metallo-proteinase-inhibitorer
PT788356E (pt) Metodo e composicoes para a inibicao de proteina-quinases.
DE60123771D1 (de) Schmiermittelzusammensetzungen die durch estersubstituierte gehinderte phenolantioxidantien enthalten
NL300219I1 (nl) Tetrahydrofuran antischimmelmiddelen.
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
RS50142B (sr) Stabilni rastvori meloksikama, visoke koncentracije
ES2192854T3 (es) Ibuprofen de rapida disolucion que contiene composiciones con actividad analgesica.
MXPA06000474A (es) Composiciones farmaceuticas para aplicaciones topicas.
RS50112B (sr) Derivati izosorbid mononitrata i njihova upotreba kao vazodilatacionih agensa sa redukovanom tolerancijom
ES2066057T3 (es) Compuestos de organosilano.
DE69839781D1 (en) Heterocyclische topoisomerase toxine
DE69917000D1 (de) Butorphanol enthaltende formulierungen mit verzögerter freisetzung
BR9913757A (pt) Composto, e, agentes controladores de praga
BRPI0411664A (pt) composição oral antiplaca aquosa estável
ES2108819T3 (es) Aditivos para carburante.
AP2001002310A0 (en) Agrochemical composition.
BR9709168A (pt) Soluções aquosas de esterquats altamente concentradas
RS50033B (sr) Derivati etansulfonil-piperidina